Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy, with Focus on PM577 Prime Editor.

Prime Medicine to host a virtual event on November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson's Disease. The company expects to file an IND/CTA for PM577, a Prime Editor for H1069Q-driven Wilson's Disease, in H1 2026, with initial clinical data expected in 2027. The event will feature presentations from the company's management team and Dr. Michael Schilsky, highlighting Prime Medicine's strategy to develop Prime Editors for genetic liver diseases.